Marc Darrow, MD, JD | StemCellInstitute.com | Updated November 18, 2026

A reader describes an ankle inflammation problem diagnosed by a podiatrist as “perennial tendinitis,” treated with five to six months of physical therapy and meloxicam 15 mg for pain and inflammation.

The intended diagnosis is likely peroneal tendinitis, although the exact term should be confirmed. The question does not tell us where the pain is located, whether treatment helped, or whether imaging has been performed. Those missing details matter.

If symptoms remain limiting after several months, I would want to know whether the original diagnosis explains the current problem. Persistent pain does not automatically mean that physical therapy failed or that surgery is necessary. It may mean that the tendon, the surrounding structures, and the rehabilitation plan need another look.

The people I see with persistent outer-ankle pain often have already tried rest, ice, medication, braces, shoe inserts, walking boots, or extensive physical therapy. Some have also tried a cortisone injection. Their concern is understandable: why does the ankle still hurt after so much treatment?

The answer begins with diagnostic clarity. A painful tendon, a tendon tear, a slipping tendon, and an unstable ankle can occur together, but they are different treatment targets.

For someone exploring regenerative medicine, the next question is often whether Wharton’s jelly, bone marrow concentrate, or a treatment described as “stem cells” might offer something different. These approaches are being investigated for their potential to influence the environment around damaged tissue. The useful question is what a particular preparation contains and what evidence supports its use for this particular tendon.

What are the peroneal tendons?

The peroneus longus and peroneus brevis tendons run along the outside of the ankle, passing behind the outer ankle bone. They help turn the foot outward and support stability during walking and activity. The peroneus brevis attaches to the base of the fifth metatarsal on the outside of the foot. The peroneus longus travels beneath the foot toward the first metatarsal and medial cuneiform, contributing to foot support and push-off.

A rolling injury, recurrent ankle sprains, or repetitive running and jumping can strain these structures. Sudden increases in training load and footwear that does not suit the activity can also contribute. Inflammation of the surrounding sheath, tendon thickening, and mechanical irritation may coexist.

Pain behind or below that outer ankle bone can fit a peroneal tendon disorder. Pain centered elsewhere may point to a different structure. A swollen ankle is a symptom, not a diagnosis of which tissue is responsible.

Is it inflammation, tendinopathy, a tear, or instability?

“Tendinitis” emphasizes inflammation. “Tendinopathy” is a broader clinical term for tendon pain and impaired function; it does not mean inflammation must be absent. Tendon-sheath inflammation, degenerative changes, and tearing may overlap.

The ESSKA-AFAS consensus separates peroneal tendon disorders into tendinopathy, tearing or rupture, and instability or dislocation. This distinction matters because treatment depends on the type of problem, not simply how long the ankle has hurt. The consensus is expert guidance informed by a literature review, with much of the underlying evidence at lower levels. (1)

Repeated snapping behind the outer ankle bone raises a different question from soreness after a long walk. Giving way may involve ankle ligaments as well as tendons. Weakness or persistent focal swelling also deserves assessment rather than an assumption that more anti-inflammatory medication is the answer.

Outer-ankle pain is not always a peroneal tendon problem

The differential diagnosis includes lateral ankle-ligament injury, instability, impingement, an unrecognized fracture, cartilage-and-bone injury of the talus, and peroneal tendon disease. A clinical review of peroneal tears emphasizes that several of these conditions can occur together after an inversion injury, when the sole turns inward. (2)

This is why the examination should assess the joint and ligaments as well as the tendons. Pain with resisted outward movement of the foot may support tendon involvement, but tenderness alone does not establish a tear. Reproducible snapping behind the outer ankle bone suggests a different mechanical problem from pain at the tendon’s attachment.

How tendon tears can affect walking

A 2022 study examined gait in 65 patients with surgically confirmed unilateral peroneal tendon tears. Compared with the opposite limb, the affected side showed changes in ankle and hindfoot motion, reduced ankle power, and diminished mechanical performance. More severe tear patterns were associated with greater impairment. (3)

This helps explain why a tendon problem can affect push-off and walking rather than causing only local soreness. It does not mean that everyone with these symptoms has a tear, or that the study establishes which treatment is best.

Why can symptoms persist despite five to six months of therapy?

The duration of therapy does not tell us what was treated or whether the program matched the diagnosis. Useful questions include:

  • Was pain improving, unchanged, or worsening?
  • Did exercises build strength and walking tolerance, or repeatedly provoke swelling and pain?
  • Was daily walking, work, or sport continuing to exceed what the ankle could tolerate?
  • Was instability, tendon snapping, or a possible tear assessed?
  • Could joint disease, a bone injury, or nerve irritation be contributing?

Several problems can coexist. An ankle that repeatedly gives way can keep challenging the tendons, while pain can alter walking and make progressive strengthening difficult. Simply repeating an unchanged program may not resolve the reason progress has stalled.

Why is Wharton’s jelly being studied for tendon problems?

Wharton’s jelly is the gelatinous connective tissue surrounding the blood vessels in an umbilical cord. Its matrix contains substances such as collagen and hyaluronic acid. Donated cord tissue can be processed into allograft products, but different processing methods produce different preparations.

The research interest is understandable: tendon repair depends on an organized extracellular matrix, cellular communication, and a suitable mechanical environment. Investigators are exploring whether cord-derived materials might contribute useful matrix components or biological signals. These are proposed mechanisms, not established clinical effects in a painful peroneal tendon.

A 2020 laboratory study characterized one Wharton’s-jelly formulation and reported growth factors, cytokines, hyaluronic acid, and extracellular vesicles, including particles described as exosomes. It did not test treatment of patients with peroneal tendinopathy. Detecting these components does not establish their effective dose, activity after injection, or ability to restore tendon strength. (4)

Wharton’s jelly is not automatically a live stem-cell injection

Three ideas need to be kept separate: the cells present in native umbilical-cord tissue, the contents of a processed tissue product, and the effects demonstrated after administering that product. They are not interchangeable.

A label such as “Wharton’s jelly” or “umbilical-cord tissue” does not, by itself, verify a viable stem-cell dose or the cells’ function. Product-specific testing would be needed to substantiate such claims. Likewise, improvement after a tissue allograft does not prove that donor stem cells survived, became tendon cells, or rebuilt the tendon.

The plausible research possibilities include effects from matrix-associated substances and signaling rather than simply replacing damaged tendon with new cells. Which mechanisms matter clinically, and for which products, still needs to be established.

What does human Wharton’s-jelly tendon research show?

Posterior tibial tendon degeneration: an encouraging early observation

A 2025 observational report described 26 patients with posterior tibial tendon dysfunction who had not responded adequately to conservative care. Investigators reported improvements in pain and other patient-reported outcomes over approximately three to four months following Wharton’s-jelly allograft application. No adverse events were reported. (5)

This is relevant as early human tendon research, but the posterior tibial tendon supports the inner ankle and arch; it is not a peroneal tendon. There was no randomized control group, follow-up was short, and several authors were affiliated with the product manufacturer. These limitations prevent a conclusion that the product caused the improvement, restored tendon structure, or would work for outer-ankle pain. No reported adverse events in 26 patients does not establish long-term safety.

Achilles tendinosis: a case report involving several treatments

Another 2025 report described a woman with longstanding Achilles insertional tendinosis treated with a Wharton’s-jelly allograft, extracorporeal pulsed-activation therapy, and class IV laser treatment. The authors reported that pain decreased from 10/10 to 0/10 by week 13. (6)

That is a promising individual outcome, but the contribution of Wharton’s jelly cannot be separated from the other treatments or the natural course of symptoms. Several authors were affiliated with the manufacturer. A single combined-treatment case does not establish effectiveness for Achilles disease, much less peroneal tendinopathy.

How far can these findings take us?

These reports justify more investigation. They do not justify promising that Wharton’s jelly will heal a peroneal split tear, prevent surgery, or permanently stabilize an ankle. The research reviewed for this article did not identify a controlled human trial establishing Wharton’s-jelly effectiveness for peroneal tendinopathy.

The important future questions are whether improvements exceed those from rehabilitation or a comparison injection, whether tendon structure and strength improve, how durable any benefit is, and which patients and preparations are most appropriate.

Bone marrow concentrate and the possibilities of stem-cell-related treatment

Bone marrow aspirate concentrate, or BMAC, is prepared from the patient’s own marrow. It contains a mixture of marrow cells, platelets, and signaling substances, including a small population of stromal or progenitor cells. It is not a purified stem-cell dose.

The therapeutic rationale is to influence tissue repair and inflammatory signaling. That is different from demonstrating that injected cells become new tendon. For a patient, meaningful outcomes would include improved walking tolerance, less pain, and better strength—not simply a claim that a preparation contains cells.

A 2021 retrospective study followed 15 patients with persistent Achilles tendinopathy treated with iliac-crest marrow concentrate. Average pain scores fell from 6.26 before treatment to 2.60 at 48 weeks, and no donor-site or injection-site complications were reported. There was no comparison group. These findings suggest a possibility worth studying, but they do not establish peroneal-tendon efficacy, tendon regeneration, or superiority over Wharton’s jelly or PRP. (7)

What is the difference between Wharton’s jelly, BMAC, and PRP?

Preparation Source and research rationale What remains uncertain for peroneal tendons
Wharton’s-jelly tissue allograft Donated cord connective tissue; investigated for matrix-associated and signaling properties. Product composition, clinical benefit, durability, and risks for this diagnosis. It is not automatically a verified viable stem-cell preparation.
Bone marrow aspirate concentrate The patient’s marrow; a mixed preparation investigated for repair-related cellular and signaling effects. Which patients benefit and whether it outperforms other care. It is not purified stem cells.
PRP The patient’s blood; concentrated platelets and associated signaling substances. Peroneal-specific effectiveness and optimal preparation and protocol. PRP is not a stem-cell treatment.

None can be selected responsibly from the diagnosis name alone. The exact preparation, intended target, evidence, and regulatory pathway matter.

U.S. regulatory status: research interest is different from approval

The FDA identifies Wharton’s jelly among regenerative products marketed without required approval and states that these regenerative therapies have not been approved for orthopedic conditions such as tendinitis. FDA registration, a tissue listing, or a ClinicalTrials.gov entry does not establish approval or lawful marketing. A product’s regulatory pathway depends on its processing and intended use. (8)

A published study describing an allograft as “structural supplementation” does not by itself establish that a particular tendon injection qualifies for an exemption. Any proposed treatment needs a product-specific explanation of its status and, when investigational, the applicable FDA-authorized research pathway. This article describes research possibilities; it does not establish that the clinic offers a particular cord-tissue product.

Potential risks include infection or contamination, inflammatory or immune reactions, bleeding, pain flare, and injury to nearby structures. Marrow collection adds harvest-site risks. Preliminary reports without complications cannot rule out uncommon or delayed problems.

Would ultrasound or MRI help?

Imaging is most useful when it answers a specific question: Is there a tear? Is the tendon moving abnormally? Is the pain coming from an adjacent joint or bone?

Why a reassuring MRI may not settle the question

In a study published online in 2021 and in a 2022 journal issue, researchers compared MRI with operative findings in 82 patients undergoing surgery for chronic lateral ankle instability. Peroneal pathology was identified during surgery in 76 patients (92.7%), whereas MRI identified it in 40 (48.8%). (9)

These were selected surgical patients with a high prevalence of tendon abnormalities. The findings support correlating MRI with symptoms and examination; they do not establish that MRI is unreliable for every patient or that a negative scan requires surgery.

What newer comparisons show

A 2024 study compared ultrasound and MRI with operative findings in 21 patients who underwent surgery for suspected peroneal tendon disease. Both tests performed well for several abnormalities; dynamic ultrasound identified tendon subluxation more sensitively in this small group. Because everyone was selected for surgery, these results cannot be applied directly to all people with ankle pain. (10)

A 2025 systematic review and meta-analysis included 12 studies. Ultrasound had higher pooled sensitivity for tears, but the studies were heterogeneous and all were judged at high risk of bias. The authors could not confidently establish that either test was superior overall. (11)

Ultrasound can observe the tendons during movement. MRI provides a broader assessment of deeper and neighboring structures. Neither replaces an examination, and a report describing mild tendinosis should not automatically explain every symptom.

What does meloxicam 15 mg do?

Meloxicam is an NSAID that can reduce pain and inflammation. It does not mechanically repair a tendon tear or stop a tendon from slipping out of position.

For adults, 15 mg is the maximum recommended daily oral dose. It should not be increased independently. The prescribing information advises the lowest effective dose for the shortest appropriate duration. If it has been taken regularly for months, the prescriber should reassess benefit, medication interactions, blood pressure, and whether kidney function or other laboratory monitoring is needed. Important risks include gastrointestinal bleeding, kidney injury, and cardiovascular events. Avoid adding ibuprofen or naproxen unless specifically directed. (12)

Black stools, vomiting blood, chest pain, or shortness of breath require urgent medical attention. Pain relief from medication should not be interpreted as proof that the underlying tendon problem has healed.

What nonsurgical treatment may still be useful?

The aim is to restore tolerable loading and function while addressing factors that continue to aggravate the ankle. Depending on examination findings, this may involve modifying activity, reviewing footwear or support, and adjusting strengthening and balance exercises. A boot or brace is a selected intervention, not an automatic long-term solution.

The ESSKA-AFAS panel supports conservative care and gradual return to movement and tendon loading when appropriate. It also discusses shockwave therapy after initial measures fail, while acknowledging limited peroneal-specific evidence. Treatment should follow the identified pathology rather than a single protocol for every painful ankle. (1)

Corticosteroid injections: the tendon sheath is different from the tendon

A steroid injection may reduce pain associated with an inflamed tendon sheath. Its position matters: injection into tendon tissue raises different concerns from an ultrasound-guided injection around the tendon within its sheath.

A 2019 retrospective series included 96 patients receiving 109 ultrasound-guided peroneal tendon-sheath injections. Twenty-four patients (25%) later underwent peroneal tendon surgery. Among the 87 patients reporting duration of relief, the results were:

  • 43.7%: zero to one week.
  • 12.6%: two to six weeks.
  • 6.9%: seven to twelve weeks.
  • 36.8%: more than twelve weeks.

Two complications were reported: temporary sural-nerve irritation and progression of a peroneus longus tear. With no randomized comparison group, this series cannot establish that injection prevents surgery or repairs tendon tissue. It does show that duration of symptom relief varied substantially. (13)

Why tendon health remains part of the discussion

A separate retrospective report described 13 patients requiring repair of hand-tendon ruptures after corticosteroid injections. This supports caution about tendon complications, but it is not a study of peroneal tendons and cannot provide an ankle-specific rupture rate or prove that each rupture was caused by the injection. (14)

The decision should account for any tear, the proposed injection location, previous injections, and the purpose of treatment. Short-term pain reduction is a different outcome from tendon healing.

Where does PRP fit alongside these possibilities?

PRP is prepared from blood; bone marrow preparations contain a different mixture of cells and signaling substances. Evidence for another tendon or for ankle arthritis does not establish effectiveness for peroneal tendinopathy.

A 2021 narrative review discussed the biological rationale and clinical literature for PRP across several musculoskeletal conditions. It describes concentrated platelets and their signaling substances, while also identifying differences in preparations and applications. It is useful background, but evidence across tendon disorders cannot be assumed to demonstrate benefit for the peroneal tendons. (15)

The ESSKA-AFAS consensus found insufficient evidence to support routine PRP use for peroneal tendon pathology. It should not be presented as a proven way to repair these tendons or avoid surgery. (1)

Before considering an injection, the target and the condition being treated must be clear. An injection cannot reliably correct a tendon that repeatedly dislocates or reconnect a complete rupture. Risks include infection, bleeding, pain flare, and injury to nearby tissues. Evidence limitations should be part of the discussion, rather than using the word “regenerative” as a guarantee.

What about ultrasound-guided ultrasonic tenotomy?

For selected persistent insertional tendon problems, a clinician may discuss percutaneous ultrasonic tenotomy, a procedure that uses an ultrasound-guided instrument to remove diseased tissue through a small skin opening. It is not arthroscopy.

A 2019 case report described successful treatment of insertional peroneus brevis tendinopathy with this approach; the patient remained symptom-free at six months, with no reported complications. That is an encouraging individual result, not a controlled trial or a reliable estimate of success for other patients. (16)

The suitability of a procedure depends on whether the pain actually comes from the tendon attachment. A technique directed at that area does not address every tear or a tendon that repeatedly dislocates.

When is a surgical opinion reasonable?

Persistent disability, a symptomatic tear or rupture, or recurrent tendon displacement may justify review by a foot-and-ankle specialist. Surgery is not determined by the calendar alone. The examination, imaging, activity requirements, and response to appropriate nonsurgical care need to fit together.

Surgical options vary with the problem. A repairable tear may be cleaned up and repaired; more extensive damage may require joining the damaged tendon to its neighbor or reconstruction. Recurrent displacement may require repair of the retaining structures, sometimes with additional correction. A 2020 review describes these distinctions rather than treating all peroneal tears as the same operation. (2)

A new pop with substantial weakness, inability to bear weight after injury, or a hot red ankle with fever needs prompt assessment.

Exploring regenerative possibilities starts with the right diagnosis

After months of treatment, the useful question is whether the current diagnosis and treatment plan still match the symptoms. Peroneal tendinopathy, tendon tearing, tendon instability, and ankle-ligament problems can overlap, but they are not interchangeable.

Wharton’s jelly and marrow-based treatments offer research directions worth examining, particularly when standard care has not produced adequate improvement. Their potential should be discussed with the same care as their limitations. The aim is a treatment decision supported by the diagnosis and the evidence, rather than a promise attached to the words “stem cells.”

References

1 van Dijk PA, Miller D, Calder J, et al. The ESSKA-AFAS international consensus statement on peroneal tendon pathologies. Knee Surgery, Sports Traumatology, Arthroscopy. 2018;26(10):3096-3107. doi:10.1007/s00167-018-4971-x.

2 Danna NR, Brodsky JW. Diagnosis and Operative Treatment of Peroneal Tendon Tears. Foot & Ankle Orthopaedics. 2020;5(2):2473011420910407. doi:10.1177/2473011420910407.

3 Chinitz N, Bohl DD, Reddy M, Tenenbaum S, Coleman S, Brodsky JW. Preoperative Gait Analysis of Peroneal Tendon Tears. Foot & Ankle International. 2022;43(2):233-243. doi:10.1177/10711007211036876.

4 Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications. Journal of Orthopaedic Surgery and Research. 2020;15(1):49. doi:10.1186/s13018-020-1553-7.

5 Baravarian B, Kwon G, Shou J, Lambert N, Lee A, Castle E, Barrett T. An Observational Cohort Study of Wharton’s Jelly Tissue Allografts for Posterior Tibial Tendon Degeneration. Biomedicines. 2025;13(10):2398. doi:10.3390/biomedicines13102398.

6 Parker RG, Lambert N, Shou JJ, Woods CG, Barrett TC. A Case Report on Umbilical Cord Connective Tissue Allograft Application in Combination with Other Modalities for Defects of the Achilles Tendon. Journal of the American Podiatric Medical Association. 2025;115(5):23-225. doi:10.7547/23-225.

7 Thueakthong W, de Cesar Netto C, Garnjanagoonchorn A, Day J, Friedman G, Auster H, Tan E, Schon LC. Outcomes of iliac crest bone marrow aspirate injection for the treatment of recalcitrant Achilles tendinopathy. International Orthopaedics. 2021;45(9):2423-2428. doi:10.1007/s00264-021-05112-3.

8 U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. June 3, 2021. Accessed November 18, 2026.

9 Clair BL, Winder ML, Neubauer EF. Open Evaluation of the Peroneal Tendons Should Be Considered in Patients With Chronic Lateral Ankle Instability Undergoing Ankle Arthroscopy With Lateral Ankle Stabilization. The Journal of Foot and Ankle Surgery. 2022;61(6):1177-1181. doi:10.1053/j.jfas.2021.10.020.

10 Melville DM, Taljanovic MS, Gimber LH, Miller M, Ahmad A, Sepich D, Latt LD. Comparison of Ultrasound and MRI with Intraoperative Findings in the Diagnosis of Peroneal Tendinopathy, Tears, and Subluxation. Journal of Clinical Medicine. 2024;13(3):740. doi:10.3390/jcm13030740.

11 Ghandour S, Mercer RW, Strahan JA, Bejarano-Pineda L, Stewart ZE. Diagnostic accuracy of MRI and US for peroneal tendon tears: a systematic review and meta-analysis. European Radiology. 2025;35(9):5360-5368. doi:10.1007/s00330-025-11472-w.

12 DailyMed. Bryant Ranch Prepack. Meloxicam tablets: prescribing information. Updated November 2, 2026. U.S. National Library of Medicine.

13 Fram BR, Rogero R, Fuchs D, Shakked RJ, Raikin SM, Pedowitz DI. Clinical Outcomes and Complications of Peroneal Tendon Sheath Ultrasound-Guided Corticosteroid Injection. Foot & Ankle International. 2019;40(8):888-894. doi:10.1177/1071100719847629.

14 Lu H, Yang H, Shen H, Ye G, Lin XJ. The clinical effect of tendon repair for tendon spontaneous rupture after corticosteroid injection in hands: A retrospective observational study. Medicine (Baltimore). 2016;95(41):e5145. doi:10.1097/MD.0000000000005145.

15 Collins T, Alexander D, Barkatali B. Platelet-rich plasma: a narrative review. EFORT Open Reviews. 2021;6(4):225-235. doi:10.1302/2058-5241.6.200017.

16 Sussman WI, Hofmann K. Treatment of Insertional Peroneus Brevis Tendinopathy by Ultrasound-Guided Percutaneous Ultrasonic Needle Tenotomy: A Case Report. The Journal of Foot and Ankle Surgery. 2019;58(6):1285-1287. doi:10.1053/j.jfas.2019.04.004.

This educational article does not replace an individual medical assessment.